Global, regional and national burden of primary liver cancer by subtype
Open accessAbstract
Introduction Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) are the two main histological subtypes of primary liver cancer. Estimates of the burden of liver cancer by subtype are needed to facilitate development and evaluation of liver cancer control globally. We provide worldwide, regional and national estimates of HCC and iCCA incidence using high-quality data. Methods We used population-based cancer registry data on liver cancer cases by histological subtype from 95 countries to compute the sex- and country-specific distributions of HCC, iCCA and other specified histology. Subtype distributions were applied to estimates of total liver cancer cases for 2018 from the Global Cancer Observatory. Age-standardised incidence rates (ASRs) were calculated. Results There were an estimated 826,000 cases of liver cancer globally in 2018: 661,000 HCC (ASR 7.3 cases per 100,000); 123,000 iCCA (ASR 1.4) and 42,000 other specified histology (ASR 0.5). HCC contributed 80% of the world total liver cancer burden followed by iCCA (14.9%) and other specified histology (5.1%). HCC rates were highest in Eastern Asia (ASR 14.8), Northern Africa (ASR 13.2) and South-Eastern Asia (ASR 9.5). Rates of iCCA were highest in South-Eastern Asia (ASR 2.9), Eastern Asia (ASR 2.0), Northern Europe, the Caribbean and Central America and Oceania (ASR all 1.8). Conclusion We have shown the importance of uncovering the distinct patterns of the major subtypes of liver cancer. The use of these estimates is critical to further develop public health policy to reduce the burden of liver cancer and monitor progress in controlling HCC and iCCA globally.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · see citing works
Self-citationEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406 · see citing works
Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482 · see citing works
Marrero, J. A., Kulik, L., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,549 · see citing works
Schweitzer, A., Horn, J., Mikolajczyk, R., Krause, G., & Ott, J. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61412-x · Cited by 2,747 · see citing works
Blach, S., Zeuzem, S., Manns, M. P., et al. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30181-9 · Cited by 2,005 · see citing works
Williams, J. H., Phillips, T. D., Jolly, P. E., Stiles, J. K., Jolly, C. M., & Aggarwal, D. (2004) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.5.1106 · Cited by 1,786 · see citing works
Global burden of aflatoxin-induced hepatocellular carcinoma: A risk assessment
Liu, Y., & Wu, F. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.0901388 · Cited by 1,224 · see citing works
Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study
Rumgay, H., Shield, K. D., Charvat, H., Ferrari, P., Sornpaisarn, B., Obot, I. S., Islami, F., Lemmens, V. E. P. P., Rehm, J. T., & Soerjomataram, I. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00279-5 · Cited by 690 · see citing works
Self-citationKeiser, J., & Utzinger, J. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00012-09 · Cited by 629 · see citing works
International trends in hepatocellular carcinoma incidence, 1978–2012
Petrick, J. L., Florio, A. A., Znaor, A., Ruggieri, D., Laversanne, M., Alvarez, C. S., Ferlay, J., Valery, P. C., Bray, F., & McGlynn, K. A. (2020) · International Journal of Cancer · doi:10.1002/ijc.32723 · Cited by 594 · see citing works
Self-citationWelzel, T. M., McGlynn, K. A., Hsing, A. W., OʼBrien, T. R., & Pfeiffer, R. M. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj234 · Cited by 371 · see citing works
Liver cancer: Descriptive epidemiology and risk factors other than HBV and HCV infection
Chuang, S.-C., Vecchia, C. L., & Boffetta, P. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.10.040 · Cited by 358 · see citing works
Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide
Maucort‐Boulch, D., de Martel, C., Franceschi, S., & Plummer, M. (2018) · International Journal of Cancer · doi:10.1002/ijc.31280 · Cited by 358 · see citing works
Cancer incidence in five continents : a technical report
Doll, R., Payne, P. M., & Waterhouse, J. A. H. (1966) · Springer eBooks · Cited by 321 · see citing works
Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012
Florio, A. A., Ferlay, J., Znaor, A., Ruggieri, D., Alvarez, C. S., Laversanne, M., Bray, F., McGlynn, K. A., & Petrick, J. L. (2020) · Cancer · doi:10.1002/cncr.32803 · Cited by 304 · see citing works
Self-citationRising trends in cholangiocarcinoma: Is the ICD classification system misleading us?
Khan, S. A., Emadossadaty, S., Ladep, N. G., Thomas, H. C., Elliott, P., Taylor-Robinson, S. D., & Toledano, M. B. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.11.015 · Cited by 290 · see citing works
Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors
Baecker, A. S., Liu, X., Vecchia, C. L., & Zhang, Z. (2018) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000428 · Cited by 277 · see citing works
Approaches, Progress, and Challenges to Hepatitis C Vaccine Development
Bailey, J. R., Barnes, E., & Cox, A. L. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.060 · Cited by 252 · see citing works
Petrick, J. L., Thistle, J. E., Zeleniuch‐Jacquotte, A., Zhang, X., Wactawski‐Wende, J., Dyke, A. L. V., Stampfer, M. J., Sinha, R. R., Sesso, H. D., Schairer, C., et al. (2018) · The American Journal of Gastroenterology · doi:10.1038/s41395-018-0207-4 · Cited by 109 · see citing works
Comparison of liver cancer incidence and survival by subtypes across seven high‐income countries
Rutherford, M. J., Arnold, M., Bardot, A., Ferlay, J., De, P., Tervonen, H. E., Little, A. L., Bucher, O., Jacques, N. S., Gavin, A., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33767 · Cited by 89 · see citing works
Self-citationClinical presentation, risk factors and staging systems of cholangiocarcinoma
Plentz, R. R., & Malek, N. P. (2015) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2015.02.001 · Cited by 85 · see citing works
Songserm, N., Promthet, S. S., Sithithaworn, P., et al. (2011) · Cancer Epidemiology · doi:10.1016/j.canep.2011.11.007 · Cited by 79 · see citing works
Hepatitis B and C virus infections in hepatocellular carcinoma and cirrhosis in Mongolia
Dondog, B., Lise, M., Dondov, O., Baldandorj, B., & Franceschi, S. (2011) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e32833f0c8e · Cited by 39 · see citing works
Yang, C., Lü, Y., Xia, H., Liu, H., Pan, D., Yang, X., & Sun, G. (2019) · Nutrition and Cancer · doi:10.1080/01635581.2019.1664602 · Cited by 28 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064 · see citing works
Self-citationGlobal burden of primary liver cancer in 2020 and predictions to 2040
Rumgay, H., Arnold, M., Ferlay, J., Lesi, O., Cabasag, C. J., Vignat, J., Laversanne, M., McGlynn, K. A., & Soerjomataram, I. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.021 · Cited by 2,197 · see citing works
Self-citationAdjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391 · see citing works
Liu, X., Cai, Y., Zhang, Y., Zhang, H., Tian, S., Gong, Y., Song, Q., Chen, X., Ma, X., Wen, Y., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107526 · Cited by 39 · see citing works
- Authors
- Rumgay, H., Ferlay, J., de Martel, C., Georges, D., Ibrahim, A. S., Zheng, R., Wei, W., Lemmens, V. E. P. P., & Soerjomataram, I.
- Affiliations
- Centre international de recherche sur le cancer (FR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Erasmus MC (NL)
- Corresponding author
- Rumgay, Harriet
- ORCID
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 161
- Pages
- 108-118
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W4200274169
- Cited by
- 615
- References
- 25
- Citations by year
- 2026: 157 · 2025: 206 · 2024: 116 · 2023: 105 · 2022: 31
- FWCI
- 34.99
- Type
- journal article
- Language
- en
- Open access
- green
- pure.eur.nl
- Licence
- Locations
- European Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, intrahepatic cholangiocarcinoma, primary liver cancer, cancer incidence, histological subtypes, age-standardized incidence rate, global cancer burden, regional variation in incidence, cancer control policy
- MeSH terms
- Global Burden of Disease, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Registries, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
